|
Powered by Cell Signaling Technology |
Site Information |
---|
QKRHARVtVKYDRRE SwissProt Entrez-Gene |
Blast this site against: NCBI SwissProt PDB |
Site Group ID: 449098 |
In vivo Characterization | |
---|---|
Methods used to characterize site in vivo: | |
Relevant cell line - cell type - tissue: |
Upstream Regulation | |
---|---|
Kinases, in vitro: | |
Treatments: |
Downstream Regulation | |
---|---|
Effects of modification on PPP1R14A: |
References | |
---|---|
Eto M, et al. (2007) Phosphorylation-induced conformational switching of CPI-17 produces a potent myosin phosphatase inhibitor. Structure 15, 1591-602
18073109 Curated Info |
|
Dakshinamurti S, Mellow L, Stephens NL (2005) Regulation of pulmonary arterial myosin phosphatase activity in neonatal circulatory transition and in hypoxic pulmonary hypertension: a role for CPI-17. Pediatr Pulmonol 40, 398-407
16130142 Curated Info |
|
Hayashi Y, et al. (2001) Defining the structural determinants and a potential mechanism for inhibition of myosin phosphatase by the protein kinase C-potentiated inhibitor protein of 17 kDa. J Biol Chem 276, 39858-63
11517233 Curated Info |